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INTRODUCTION
Various diagnostic tools for atopic dermatitis (AD) have been 
proposed due to the lack of definitive biomarkers and the 
marked diversity of its clinical features.1,2 Hanifin and Rajka’s 
criteria were developed for AD diagnosis at the individual level 
in a hospital setting.3 As the criteria were based on the empiri-
cal experiences of AD experts, they encompass numerous, mi-
nor features unfamiliar to untrained examiners. Subsequently, 
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the UK Working Group refined the criteria to improve their 
practical applicability (UK’s criteria) that included a minimum 
set of valid and reliable items for use in both hospital and com-
munity settings.4-6 Meanwhile, questionnaire-based diagnostic 
criteria for AD, including the International Study for Asthma 
and Allergies in Childhood (ISAAC), were developed for epide-
miological surveys in a community setting.1,7-9
Hospitals-detected AD patients who are diagnosed in the hos-
pitals are known to have more severe symptoms than those 
who are detected by community-based surveys. In previous 
studies on the severity of AD, 67.9%-86.1% of AD patients were 
mild in community-based surveys, while 32.7% of AD patients 
were mild in hospital-based surveys.10-13 Interestingly, 36% of 
AD schoolchildren, who were detected by community-based 
surveys, did not consulted doctors (probably with mild AD), 
suggesting the importance of epidemiological surveys in given 
communities.11 In fact, the majority of participants (i.e., both 
children and their parents) have a strong desire to be consulted 
on their skin conditions at the individual level through epide-
miological surveys. Taken together, it is suggested that continu-
ous monitoring on AD prevalence in given communities or in-
dividuals are very important for efficient AD management. 
As a simple, convenient diagnostic tool for epidemiological 
surveys, the ISAAC was designed mainly to detect the major 
group of AD with flexural dermatitis. Therefore, it has a limit to 
detect the minor group of AD, such as non-flexural, nummular-
type AD.2,14,15 Furthermore, the ISAAC is not supposed to differ-
entiate non-AD diseases from itchy skin eruptions, such as urti-
caria due to its simplified questions on flexural dermatitis. The 
Korean Atopic Dermatitis Association (KADA) aimed to devise 
more comprehensive, accurate, questionnaire-based diagnostic 
criteria for AD, for use not only in the context of epidemiological 
surveys, but also to provide medical advice at individual levels. 
For this purpose, we designed new diagnostic criteria for child-
hood AD; i.e., Reliable Estimation of Atopic dermatitis in Child-
Hood (REACH), encompassing questions not only on relapsing 
dermatitis (flexural or non-flexural), but also on AD-related fac-
tors (atopy history and environmental or aggravating factors). 
Figure. Flow chart to develop the REACH as new diagnostic criteria for childhood AD.
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The REACH was developed using a derivation set including 
both elementary school (7-12 years of age) and preschool (4-6 
years of age) children. The criteria were then further validated 
using a different validation set covering the same age group (Fig-
ure). We propose new full-questionnaire-based REACH criteria 
for childhood AD, which can be used as a different instrument 
for epidemiological surveys of childhood AD in future. 
MATERIALS AND METHODS
Gold standard for the ‘1-year AD prevalence’ 
As a gold standard for the 1-year AD prevalence, dermatolo-
gists’ skin examination should be performed at least twice a 
year for the same group of children. For this study, we distribut-
ed the draft or final version of questionnaires together with the 
ISAAC prior to skin examination and performed the first skin 
examination by 2 dermatologists in June-July. All question-
naires of the draft and final version were answered by parents. 
From the skin examination, children were classified into 1 of 
the 3 groups of ‘AD’, ‘non-AD’, and ‘undetermined’. In Novem-
ber-December, the second skin examination was performed on 
children, who were classified as ‘undetermined’ on the first 
skin examination. Children, who were classified as ‘non-AD’ by 
the first skin examination, but were positive to the ISAAC, were 
also enrolled for the second skin examination. The recruited 
dermatologists were well informed about the Hanifin and Raj-
ka’s criteria3 and KDA’s criteria.16 
Definition of ‘eczema on the antecubital/popliteal fossae’ and 
‘eczema on the non-antecubital/popliteal fossae’
The major groups of AD, which manifested with eczematous 
skin lesions on the antecubital or popliteal fossa, were classified 
as ‘eczema on the antecubital/popliteal fossae.’ The minor 
group of AD, which manifested with eczematous skin lesions 
on other locations except the antecubital or popliteal fossa, 
were classified as ‘eczema on the non-antecubital/popliteal 
fossae. 
Preparation of the draft version of questionnaire
Twelve dermatologists, who were appointed as members of 
task force team (TFT), extracted candidate questions on our 
draft version from the Hanifin and Rajka’s,3 ISAAC’s,7 and KDA’s16 
criteria. To prepare questionnaire-based diagnostic criteria for 
AD, we excluded items requiring invasive laboratory tests, such 
as ‘elevated serum IgE’ and ‘immediate skin test reactivity.’ We 
also excluded items that were regarded as incomprehensible for 
people without medical background; pityriasis alba, white der-
matographism, etc. The selected items excepted them were clas-
Table 1. Draft version of questionnaire for use as a preliminary survey in the hospital and community settings 
Q1-1. Has your child had an itchy rash which was coming and going in the last 12 months? Yes □ No □
Q1-2. Has the itchy rash been detected on folds of the elbows or behind the knees? Yes □ No □
Q1-3. Has the itchy rash been detected around the neck? Yes □ No □
Q1-4. Has the itchy rash been detected under the buttock? Yes □ No □
Q1-5. Has the itchy rash been detected around the wrists or ankles? Yes □ No □
Q1-6. Have your child or your family (father, mother, brothers or sisters) had the following diseases?*
I.  Have your child or your family had symptoms of ‘atopic dermatitis’ (itchy skin rash called eczema), or been diagnosed 
with ‘atopic dermatitis’?
Yes □ No □
II.  Have your child or your family had symptoms of ‘asthma’ (frequent coughing, shortness of breath, or wheezing), or 
been diagnosed with ‘asthma’?
Yes □ No □
III.  Have your child or your family had symptoms of ‘allergic rhinitis’ (sneezing, runny nose, or stuffy nose when he/she 
DID NOT have a cold or the flu), or been diagnosed with ‘allergic rhinitis’?
Yes □ No □
Q2. Has your child had the following skin symptoms in the last 12 months?
Q2-1. Has your child intermittently felt an itchy sensation, or had wrinkles, or had darkening, around eyes? Yes □ No □
Q2-2. Has your child intermittently felt an itchy sensation, or had oozing, around ears? Yes □ No □
Q2-3. Has your child intermittently has chapped or oozing lips? Yes □ No □
Q2-4. Has your child intermittently felt an itchy sensation, had oozing, had thickening, on the hands or feet? Yes □ No □
Q2-5. Has your child intermittently felt an itchy sensation, had oozing, had thickening, on the nipples? Yes □ No □
Q3. Has your child had the following skin symptoms in the last 12 months?
Q3-1. Has your child had unusually dry skin? Yes □ No □
Q3-2. Has your child felt itchy when he (or she) was sweating? Yes □ No □
Q3-3. Has the skin symptoms aggravated by wools? Yes □ No □
Q3-4. Has the skin symptoms aggravated by soaps? Yes □ No □
Q3-5. Has the skin symptoms aggravated by foods? Yes □ No □
*‘Yes’ to at least 1 of 3 questions (I-III) is regarded as positive answer to Q1-6.
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sified into major and minor categories following our panel dis-
cussion, and based on experts’ opinions. In total, 18 questions 
were classified into 3 sets: I) 5 questions pertaining to recurrent 
skin rashes on the flexural locations (candidates for major crite-
ria; Q1-1 to Q1-5) and 3 questions were on atopic history (candi-
dates for major criteria; Q1-6); II) 5 questions were on non-flex-
ural dermatitis (candidates for minor criteria; Q2-1 to O2-5); and 
III) 5 questions on environmental or aggravating factors (candi-
dates for minor criteria; Q3-1 to Q3-5). Among candidate items 
for major criteria, questions on flexural dermatitis were selected 
from ISAAC’s criteria, and those on atopy history were selected 
from Hanifin and Rajka’s and KDA’s criteria.3,7,16 Atopy history 
was regarded as positive, when subjects responded ‘Yes’ to at 
least 1 of the 3 questions on AD, asthma, or allergic rhinitis. All 
questions were refined using non-medical language that was 
comprehensible to the general public (Table 1). 
Preliminary hospital- and community-based surveys to 
establish the final version of questionnaire 
For preparing the final version of questionnaire, we per-
formed our surveys in both hospital- and community-settings 
to select items from candidate questions of the draft version. 
For the hospital-based survey, ethics approval was obtained 
from 53 tertiary referral hospitals in Korea. A total of 1,342 chil-
dren with AD (mean age: 7.8 years), and 414 control children 
with non-AD skin disorders (mean age: 7.4 years) were en-
rolled. Non-AD skin disorders included urticaria (62.6%), con-
tact dermatitis (30.5%), and others (6.9%). 
For the community-based surveys, 5 elementary schools lo-
cated in Gwangju City, South Korea (125:54E, 35:09N) were en-
rolled. All elementary schoolchildren (7-12 years of age) who 
had submitted their completed parental consent forms before 
skin examination were enrolled. Among 1,545 elementary 
schoolchildren, 1,320 (mean age: 10.2 years) were finally en-
rolled in the study, which corresponds to an 85.4% response 
rate. From skin examination (twice) in together with the ISAAC, 
we allocated 149 participants (11.3%) to the AD group; the re-
maining 1,171 were allocated to the non-AD control group.
Derivation of the REACH in a community setting 
The questionnaire established herein (REACH) were admin-
istered to 1,129 children in 2 elementary schools and 3 pre-
schools, which were used as a derivation set. To simplify the 
questionnaire of the REACH, 3 questions on ‘personal or family 
history of atopy (AD, asthma, and allergic rhinitis)’ in the draft 
version were changed into 1 question by putting them together. 
All combination sets of ‘eczema on the antecubital/popliteal 
fossae’ and ‘eczema on the non-antecubital/popliteal fossae’ 
according to the respective minimum requirements of the 
number of minor criteria were evaluated for diagnostic accura-
cy. Next, we derived new diagnostic criteria considering the ac-
curacy of the estimated AD prevalence, low error rate (ER), and 
high Youden’s index (sensitivity+specificity – 1).
Validation of the REACH in a community setting
The REACH and ISAAC criteria were applied to 1,191 children 
drawn from 2 elementary schools and 3 preschools, which were 
used as a validation set. We compared the estimated AD preva-
lence and diagnostic accuracy of the REACH with those of the 
ISAAC. For this report, questions in the REACH were translated 
into English by 2 bilingual dermatologists, and back-translated 
into Korean by 2 other bilingual dermatologists to ensure con-
sistency.
Statistical analysis
Diagnostic accuracy was evaluated by calculating sensitivity, 
Table 2. The REACH (Reliable Estimation of Atopic dermatitis of ChildHood) questionnaire
Items 1. Is your child correspondent to the following questions?
  Q1. Has your child had an itchy rash which was coming and going in the last 12 months? Yes □ No □
  Q2. Has the itchy rash been detected on folds of the elbows or behind the knees in the last 12 months? Yes □ No □
  Q3.  Have you or your family (father, mother, brothers or sisters) had symptoms of ‘atopic dermatitis’ or ‘asthma’ or ‘allergic rhini-
tis’ before, or been diagnosed as one of the diseases before?
Yes □ No □
Items 2. Have your child had the following skin symptoms in the last 12 months?
  Q4. Has your child intermittently felt an itchy sensation, or had wrinkles, or had darkening, around the eyes? Yes □ No □
  Q5. Has your child intermittently felt an itchy sensation, or had oozing, around the ears? Yes □ No □
  Q6. Has your child intermittently has chapped or had oozing, around the lips? Yes □ No □
  Q7. Has your child intermittently felt an itchy sensation, or had thickening, or had darkening, around the neck? Yes □ No □
  Q8. Has your child intermittently felt an itchy sensation, or had oozing, or had thickening, under the buttock? Yes □ No □
  Q9. Has your child intermittently felt an itchy sensation, or had oozing, around the wrist or ankle joints? Yes □ No □
  Q10. Has your child had unusually dry skin? Yes □ No □
  Q11. Has your child felt itchy when he (or she) was sweating? Yes □ No □
Diagnosis of AD is made by ‘positive’ to ‘Q1 and Q2 or more’ (2 major) or by ‘positive’ to ‘Q1 and at least four questions among Q3 to Q11’ (1 major+4 minor). 
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specificity, positive (PPV), negative predictive value (NPV), ER, 
and Youden’s index. McNemar’s test was used to compare di-
agnostic accuracy between the REACH and the ISAAC, with re-
spect to misclassification. 
RESULTS
Establishment of the questionnaire of the REACH (Table 2)
Selection of questions on major criteria (recurrent flexural 
dermatitis)
From the analysis on the results of the draft version of ques-
tionnaire, TFT decided the cutoff value for major criteria as 70% 
of Youden’s index, as the value of 2 questions was markedly dif-
ferent with other questions. ‘Recurrent attacks of itchy rash dur-
ing the last year’ represented the most sensitive question (sen-
sitivity of 99.6% in the hospital-based survey and 94.6% in the 
community-based survey). Among four candidate questions 
on flexural dermatitis (Q1-2 to Q1-5), ‘the folds of the elbow or 
behind the knees’ was selected as major criteria due to 
Youden’s index of >70%. Other 3 questions on flexural derma-
titis, including around the neck, under the buttock, and around 
the wrist or ankle joints, were re-classified as minor criteria. 
‘Personal or family history of atopy’ was also re-classified as mi-
nor criteria due to Youden’s index of <70% (Table 3). 
Selection of questions on minor criteria
From the analysis on the results of the draft version of ques-
tionnaire, questions with a low sensitivity (<20% in any of hos-
pital- or community-based surveys) were excluded from the fi-
nal version of questionnaire. Among 5 candidate questions on 
non-flexural dermatitis (Q2-1 to Q2-5), 2 for hand/foot and nip-
ple eczema were excluded from the minor criteria due to a low 
sensitivity (<20%) in a community-based survey. Among 5 
candidate questions on environmental factors (Q3-1 to Q3-5), 3 
aggravating factors (Q3-3 to Q3-5) were excluded from the mi-
nor criteria due to their low sensitivity (<20%) in a community-
based survey (Table 3).
Establishment of the final version of questionnaire 
Questions on major criteria were finally narrowed down to 2 (Q1 
and Q2), pertaining to ‘recurrent skin rash in the last 12 months’ 
(Q1) and ‘itchy rash on the folds elbows or behind the knees’ 
(Q2). Minor criteria were indexed by nine questions (Q3-Q11): 
one for atopy history (Q3), six for localized eczema, including 
three flexural dermatitis and three non-flexural dermatitis (Q4-
Q9); and two for environmental factors (Q10 and Q11) (Table 2). 
Table 3. Diagnostic accuracy of candidate questions in the draft version of questionnaire (preliminary study conducted in hospital and community settings)
Hospital-based survey (n=1,756) Community-based survey (n=1,320)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
ER
(%)
Youden's 
index (%)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
ER
(%)
Youden's 
index (%)
Candidate Questions for Major Criteria
   Recurrent skin rash during last year 99.6 78.5 93.8 98.2   5.4 78.1 94.6 83.0 41.5 99.2 15.7 77.6
   Itchy rash on the antecubital/
      popliteal fossae
78.4 94.2 97.8 57.4 17.9 72.6 91.9 91.5 57.8 98.9   8.5 83.4
   Itchy rash around the neck 53.8 75.8 89.2 38.0 36.5 29.6 26.8 97.1 54.1 91.3 10.8 23.9
   Itchy rash on the infragluteal folds 39.5 88.2 90.7 29.7 47.2 27.7 14.8 98.2 51.2 90.1 11.2 13.0
   Itchy rash on the wrist/ankle joints 22.1 93.2 91.4 27.0 55.4 15.3 10.1 99.3 65.2 89.7 10.8   9.4
   Personal or family history of atopy 76.5 39.4 80.4 34.1 32.2 15.9 79.9 49.4 16.7 95.1 47.1 29.3
Candidate Questions for Minor Criteria
   Localized eczema
      Eye eczema 48.8 78.7 88.2 32.2 44.1 27.5 26.8 91.4 28.4 90.8 15.9 18.2
      Ear eczema 48.8 86.7 92.3 34.3 42.3 35.5 20.1 97.4 50.0 90.6 15.9 17.5
      Lip eczema 39.3 82.9 88.1 29.6 50.5 22.2 24.2 94.2 34.6 90.7 13.7 18.4
      Hand/foot eczema 34.9 80.0 85.0 27.5 61.2 14.9   9.5 96.5 32.1 86.0 16.3   6.0
      Nipple eczema 20.6 93.0 90.5 26.6 62.3 13.6   6.7 99.1 50.0 89.3 11.3   5.8
   Environmental factor
      Unusually dry skin 88.3 44.0 83.6 53.7 22.2 32.3 67.1 79.9 29.9 95.0 21.5 47.0
      Itch by sweating 79.4 57.2 85.7 46.1 25.9 36.6 70.5 81.6 32.8 95.6 19.6 52.1
      Aggravation by wools 52.0 79.5 89.1 33.8 41.5 31.5 19.1 96.2 46.3 87.3 15.2 15.3
      Aggravation by soaps 37.0 84.5 88.6 29.3 51.8 21.5   9.9 97.5 40.6 86.2 15.4   7.4
      Aggravation by foods 46.1 77.3 86.8 30.7 46.6 23.4 19.5 93.2 38.0 87.7 17.0 12.7
PPV, positive predictive value; NPV, negative predictive value; ER, error rate.
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Derivation of the diagnostic criteria of the REACH 
A total of 1,129 children from 2 different age groups of ele-
mentary school children (n=988, 7-12 years old) and preschool 
children (n=141, 4-6 years old) were enrolled in the survey as a 
derivation set. Following 2 skin examinations, 152 children 
were diagnosed with AD, yielding a standard AD prevalence 
rate of 13.5%. Non-AD children were allocated to the control 
group (n=977). Fulfillment of ‘2 major (Q1+Q2) (2M)’ for ‘ecze-
ma on the antecubtial/popliteal fossae’ and ‘1 major (Q1) plus 
4 or more minor (1M+4m)’ for ‘eczema on the non-antecub-
tial/popliteal fossae’were selected as optimal following our 
analysis of the derivation set (n=1,129 children); the estimated 
AD prevalence using our criteria was 13.4%, compared to 15.1% 
according to the ISAAC criteria. The diagnostic accuracy of the 
REACH (‘2M’ or ‘1M+4m’) was also superior to that of the 
ISAAC criteria (sensitivity, 80.3% vs 73.0%; specificity, 97.0% vs 
94.0%; PPV, 80.8% vs 65.3%; NPV, 96.9% vs 95.7%; and ER, 5.2% 
vs 8.9%) (Table 4).
Validation of the diagnostic criteria of the REACH
We repeated our survey in a validation set (n=1,191) from 2 
age groups of elementary schoolchildren (n=1,071, 7-12 years 
Table 4. Diagnostic accuracy of the REACH used in the derivation set (N=1,129) 
Diagnostic criteria AD prevalence (%)
Sensitivity
 (%)
Specificity
 (%)
PPV
 (%)
NPV
 (%)
ER
 (%)
Youden's 
index  (%)
Eczema on the antecubital/popliteal fossae
   2M 12.0 73.7 97.5 82.4 96.0 5.7 71.2
   2M+1m 11.7 72.4 97.7 83.3 95.8 5.7 70.1
   2M+2m 10.8 67.8 98.1 84.4 95.1 6.0 65.8
   2M+3m 8.9 59.2 98.9 89.1 94.0 6.5 58.1
   2M+4m 6.2 43.4 99.6 94.3 91.9 8.0 43.0
   2M+5m 3.9 27.6 99.8 95.5 89.9 9.9 27.4
Eczema on the non-antecubital/popliteal fossae
   1M 20.1 88.2 90.5 59.0 98.0 9.8 78.6
   1M+1m 18.6 86.8 92.0 62.9 97.8 8.7 78.9
   1M+2m 15.8 80.9 94.4 69.1 97.0 7.4 75.3
   1M+3m 11.8 70.4 97.3 80.5 95.5 6.3 67.7
   1M+4m 7.5 50.0 99.1 89.4 92.7 7.5 49.1
   1M+5m 4.4 30.9 99.7 94.0 90.3 9.6 30.6
Combinations
   2M OR 1M+1m 19.0 88.2 91.8 62.6 98.0 8.7 80.0
   2M OR 1M+2m 17.0 86.8 93.9 68.8 97.9 7.1 80.7
   2M OR 1M+3m 14.9 84.9 96.0 76.8 97.6 5.5 80.9
   2M OR 1M+4m* 13.4 80.3 97.0 80.8 96.9 5.2 77.3
   2M OR 1M+5m 12.6 77.0 97.4 82.4 96.5 5.3 74.4
   2M+1m OR 1M+2m 16.7 85.5 94.1 69.1 97.7 7.1 79.6
   2M+1m OR 1M+3m 14.5 83.6 96.2 77.4 97.4 5.5 79.8
   2M+1m OR 1M+4m 13.0 78.9 97.2 81.6 96.7 5.2 76.2
   2M+1m OR 1M+5m 12.2 75.7 97.6 83.3 96.3 5.3 73.3
   2M+2m OR 1M+3m 13.6 78.9 96.5 77.9 96.7 5.8 75.5
   2M+2m OR 1M+4m 12.1 74.3 97.5 82.5 96.1 5.6 71.9
   2M+2m OR 1M+5m 11.3 71.1 98.0 84.4 95.6 5.7 69.0
   2M+3m OR 1M+4m 10.3 65.8 98.4 86.2 94.9 6.0 64.2
   2M+3m OR 1M+5m 9.5 62.5 98.8 88.8 94.4 6.1 61.3
   2M+4m OR 1M+5m 6.7 46.7 99.5 93.4 92.3 7.6 46.2
ISAAC 15.1 73.0 94.0 65.3 95.7 8.9 67.0
Standard AD prevalence 13.5
*2M means recurrent eczema on the antecubital or/and popliteal fossae, and 1M means recurrent eczema on the other locations except the antecubital/popliteal 
fossae. 
AD, atopic dermatitis; PPV, positive predictive value; NPV, negative predictive value; ER, error rate; M, major criteria; m, minor criteria. 
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old) and preschool children (n=120, 4-6 years old). Following 2 
skin examinations, 141 children were diagnosed with AD, yield-
ing an AD prevalence of 11.8%. The non-AD children were allo-
cated to the control group (n=1,050). In estimated AD preva-
lence, the REACH (12.3%, 95% CI, 10.5%-14.2%), which includ-
ed 10.3% (n=123) for ‘eczema on the antecubital/popliteal fos-
sae’ and 2.0% (n=24) for ‘eczema on the non-antecubital/pop-
liteal fossae, was closer to our gold standard than the ISAAC 
(14.4%, 95% CI, 12.4%-16.4%). The REACH criteria also exhibit-
ed improved diagnostic accuracy with fewer misclassifications 
(6.4%, n=76) compared to the ISAAC (10.0%, n=119; P<0.001) 
(Table 5). Taken together, we propose the REACH diagnostic 
criteria for AD, which included ‘2 major or more’ for AD with 
eczema on the antecubital or popliteal fossae and ‘1 major and 
4 minor or more’ for AD without eczema on the antecubital or 
popliteal fossae (Table 6).
 
DISCUSSION
Heterogeneity in skin symptoms among AD patients renders 
the proposal of definitive diagnostic criteria problematic.2,15 The 
ISAAC criteria have been widely used as a standard diagnostic 
instrument for epidemiological surveys, but this system has ex-
hibited variable validity when used in different ethnic groups 
and geographical settings.14,17,18 As shown herein, overestima-
tion of AD prevalence using inaccurate questionnaires has a 
potential to make a mistake in managing childhood AD in giv-
en communities or countries. We introduce the REACH as a 
new diagnostic instrument for childhood AD with improved 
outcomes in both the estimated AD prevalence and diagnostic 
accuracy, compared to the ISAAC. 
Recurrent flexural dermatitis on the antecubital/popliteal fos-
sae is an essential component for childhood AD in population-
based surveys. Our results confirm that the antecubital/popli-
teal fossae represent the most sensitive area (sensitivity: 78.4% 
in hospital-based and 91.9% in community-based surveys) 
with respect to detection of recurrent flexural dermatitis in AD 
compared to other flexural areas. The 2 locations can be easily 
examined in a dressed status in summer. Stensen et al.19 sug-
gested that the 2 locations are important for ‘visible flexural 
dermatitis’ in UK’s criteria and can be amenable to examina-
tion while dressed.6 As flexural dermatitis only was not suffi-
cient to detect all of the AD patients, we categorized AD into 
‘eczema on the antecubital/popliteal fossae’ and ‘eczema on 
the non-antecubital/popliteal fossae’ to increase sensitivity of 
the REACH. The REACH was designed to detect not only the 
major group of AD with flexural dermatitis on the antecubital/
popliteal fossae, but also the minor group of AD to manifest 
with eczema on the non-antecubital/popliteal fossae in combi-
nation with ‘localized eczema’ (6 questions) and/or ‘environ-
mental factors’ (2 questions) and/or ‘atopic history’ (1 ques-
tion). In our validation set, inclusion of ‘eczema on the non-an-
tecubital/popliteal fossae’ improved the sensitivity from 66.7% 
to 75.2% (i.e., an 8.5% improvement) without changing the ER 
value (6.4%), compared to ‘eczema on the antecubital/poplite-
al fossae’ only. From this study, approximately 16% of child-
hood AD cases detected in community-based surveys were 
classified as the minor group of AD cases that do not have flex-
ural dermatitis on the antecubital or popliteal fossae. We cate-
gorized a set of flexural and non-flexural dermatitis (except flex-
ural dermatitis on the antecubital/popliteal fossae) as ‘localized 
eczema’ in the minor criteria of the REACH, in that they were 
highly heterogeneous among AD patients. The reduced inci-
dence of misclassification that characterizes the REACH, com-
pared to the ISAAC (P<0.001), might be due to the more in-
depth questions that were included in the former instrument. 
In contrast with the ISAAC to inquire the locations of flexural 
dermatitis simply, questions for ‘localized eczema’ in the 
REACH were prepared in detail to describe acute or chronic 
nature of eczematous skin lesions, such as oozing, thickening, 
or postinflammatory hyperpigmentation. Furthermore, the 
REACH was designed to detect the minor group of AD by ask-
ing questions at atopy history and environmental factors. 
Table 6. The summarized REACH diagnostic criteria for AD
2 major 
   or more
AD with eczema on the antecubital or popliteal fossae
1 major+
   4 minor or more
AD without eczema on the antecubital or popliteal fossae
Table 5. Diagnostic accuracy of the REACH and the ISAAC used in the validation set (N=1,191)
Diagnostic criteria AD prevalence (95% CI)
Sensitivity
(%)
Specificity 
(%)
PPV
(%)
NPV
(%)
Misclassification 
(n)
ER
(%)
REACH 12.3 (10.5%-14.2%) 75.2 96.1 72.1 96.6 76 6.4
   Eczema on the antecubital/popliteal fossae 10.3 (8.6%-12.1%) 66.7 97.2 76.4 95.6 6.4
   Eczema on the non-antecubital/popliteal fossae   2.0 (1.2%-2.8%) 8.5 98.9 50.0 88.9 11.8
ISAAC 14.4 (12.4%-16.4%) 68.8 92.9 56.4 95.7 119 10.0
Standard AD prevalence 11.8
REACH, Reliable Estimation of Atopic dermatitis of ChildHood; ISAAC, International Study for Asthma and Allergy in Childhood; AD, atopic dermatitis; PPV, positive 
predictive value; NPV, negative predictive value; ER, error rate.
REACH Criteria for Atopic Dermatitis
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Hanifin and Rajka’s and KDA’s criteria classified ‘atopy histo-
ry’ in the major criteria as an important pathogenic factor of 
AD.3,16 In contrast, we classified ‘atopy history’ in the minor cri-
teria due to its low specificity: a positive atopy history was ob-
served in 50.6% and 60.6% of non-AD children in hospital- and 
community-based surveys, respectively. These findings are 
consistent with those of a Japanese study, in which positive ato-
py history among a non-AD control group was estimated at 
44.4%.20
Ideal, worldwide-standardized tools for epidemiological sur-
veys might be impossible to formulate due to the heterogeneity 
of genetic backgrounds and environmental factors among AD 
patients. Strictly, questionnaires on childhood AD for epidemi-
ological surveys should be developed de novo for different 
countries.21 From this study, we propose the following compo-
nents might be compulsory in preparing questionnaires for 
childhood AD. First, ‘relapsing flexural dermatitis on the ante-
cubital/popliteal fossae’ is an essential component of the major 
criteria. Second, questions on ‘localized eczema,’ such as flex-
ural and non-flexural dermatitis, should be included in ques-
tionnaires, as they are unambiguous, objective signs for chil-
dren and their parents with a low recall bias. However, it is rea-
sonable to classify them into the minor criteria due to high het-
erogeneity among AD patients. Third, ‘atopy history’ is an es-
sential component for AD diagnosis as an important genetic 
factor in AD pathogenesis.22 However, questions on ‘atopy his-
tory’ are desirable to be classified in the minor criteria due to its 
low specificity. We should consider the possibility of recall bias 
or misdiagnosis in the ‘atopy history’ due to its broad spectrum 
including AD, asthma, and allergic rhinitis of whole family 
members (father, mother, and siblings). Fourth, ‘environmental 
factors’ as an important pathogenic factor of AD should be in-
cluded in questionnaires. Interestingly, ‘environmental factors’ 
might be closely related with the host factors of AD. From the 
REACH, questions on ‘unusually dry skin’ and ‘itch by sweat-
ing’ are highly positive in both hospital- and community-based 
surveys in Korea. ‘Unusually dry skin’ can be regarded as an en-
vironmental factor aggravated in winter, which is closely related 
with the host factor of abnormal barrier function, including fil-
aggrin mutation.23,24 ‘Generalized dry skin’ is frequently detect-
ed in most of the AD patients, regardless of their severity.25 ‘Itch 
by sweating’ can be regarded as an environmental factor aggra-
vated in summer, which is closely related with the host factor of 
abnormal neurogenic inflammation.26,27 Many AD patients 
complained that they could not sweat well in hot and humid 
weather, suggesting the altered neuropathological pathways 
mediating pruritus as well as sweating in the skin of AD pa-
tients.28 The Schulz-Larsen questionnaire also contains 2 ques-
tions pertaining to these factors.29,30 To our expectation, items 
for ‘localized eczema’ and ‘environmental factors’ can be modi-
fied in different countries with diverse genetic or environmen-
tal backgrounds. 
We propose that the REACH, which is designed to detect both 
major and minor groups of AD, can be used as a novel diagnos-
tic tool for epidemiological surveys of childhood AD. These 
questionnaire-based diagnostic criteria not only allow for accu-
rate estimation of AD prevalence in a given population, but can 
also be used to provide valuable medical advice for partici-
pants. The REACH exhibits greater accuracy compared to the 
ISAAC, in terms of estimating AD prevalence and diagnostic 
accuracy, with significantly reduced instances of misclassifica-
tion. Our study has limitations due to selection bias for the age 
and location. We selected 2 age groups, instead of whole-age 
groups for childhood AD, and 1 location, instead of the whole 
country. Further studies are required to validate the REACH on 
whole-age groups and the whole country, as well as in different 
countries or ethnicities in the context of large-scale, epidemio-
logical surveys.
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